{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(3)"],"submitter":["Franchini M"],"pubmed_abstract":["In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80−320). Their median age was 68 years (IQR, 56−78 years), and 62% were "],"journal":["Life (Basel, Switzerland)"],"pagination":["420"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8950373"],"repository":["biostudies-literature"],"pubmed_title":["Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience."],"pmcid":["PMC8950373"],"pubmed_authors":["Garuti M","Pecoriello A","Bellocchio E","Casari S","Frigato M","Inglese F","Puma G","Lucchini G","Tiecco G","Bianciardi L","Castelli GP","Cervi G","Bellometti SA","Montalto C","Candini M","Verzola A","Donno G","Spreafico F","Reggiani A","Stradoni R","Codeluppi V","Galavotti V","Benazzi D","Mule A","Bertoletti R","Greco G","Vesentini S","Ambrosi G","Beccaria M","On Behalf Of Convalescent Plasma Study Group","Glingani C","Zani M","Costantino MT","Crosato V","Ghirardini M","Berselli A","Santini T","Carandina F","Papalia DA","Scarduelli C","Franchini M","Pagani M","Presciuttini B","Pajola F","Capuzzo E","Grisolia G","Amato M"],"additional_accession":[]},"is_claimable":false,"name":"Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience.","description":"In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80−320). Their median age was 68 years (IQR, 56−78 years), and 62% were ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-04-08T17:34:44.691Z","creation":"2025-04-06T12:09:41.447Z"},"accession":"S-EPMC8950373","cross_references":{"pubmed":["35330170"],"doi":["10.3390/life12030420"]}}